Ratings
0
Nobody has rated this yet. Be the first!
Works
12
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study
Non-small-cell lung cancer: then and now.
Geospatial Resolution of Human and Bacterial Diversity with City-Scale Metagenomics
Bevacizumab: optimal dose, schedule, and duration of therapy.
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working group
Adjuvant treatment of stage IB NSCLC: the problem of stage subset heterogeneity.
Predictive molecular markers: has the time come for routine use in lung cancer?
Developing targeted therapies for lung cancer.
Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options.
Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma.
